Reports and summaries of sessions from the 12th Annual World Vaccine Congress that focused on influenza vaccines.
The 12th Annual World Vaccine Congress, held this year in Lyon, France, October 4-7, featured an impressive roster of speakers, delegates, and exhibitors representing a wide range of specialties, research interests, healthcare organizations, and vaccine manufacturers. The program featured experts in virology, public health, epidemiology, immunology, and vaccine research and manufacturing who covered the latest news and developments in several categories of infectious disease, including influenza.
HCPLive was there to cover the event, with daily reports and summaries of several key sessions. Below are links to recaps of sessions from the 12th Annual World Vaccine Congress that focused on influenza vaccines.
Early positive clinical trial results for a novel nasal influenza vaccine.
Vaccine expert says that there are many lessons to be learned from the response to the most recent H1N1 pandemic.
Researchers studying influenza vaccines were able to achieve immune response with a single vaccination against H1N1.
Safe and effective new nasal spray-delivered influenza vaccine could be produced quickly in high quantities during a pandemic infection.
How a massive operation of medical countermeasures was mobilized to tackle the ever-present threat of influenza in the US and overseas.
New vaccine would be the first cell-derived, recombinant protein-based influenza vaccine licensed in the US.